A Vision to Transform
Healthcare through AI
Our vision is more than an idea. It’s a tangible roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform.
This solution supports research-oriented computational cytology workflows to:
Improve clinical outcomesReduce healthcare burdens
Operating at the Intersection of Computer Science and Healthcare
In 2018, AIxMed’s founders blended their divergent, respective backgrounds to break through the traditional cytology status quo. Samuel Chen brings AI technology ingenuity and leadership experience from ASUS and Compal. Dr. Tien-Jen Liu offers medical expertise as a trained physician and serial medtech entrepreneur.
Their combined diversity of thought will make a meaningful impact in healthcare, with intuitive commercialized tools to simplify laboratory workflows and strengthen the quality of cytology analysis.
Targeted Experience Means Impactful Solutions
AIxMed unites noted leaders from multiple disciplines to positively impact cytopathology diagnosis. We are creating a ripple effect that extends from laboratories through to patients. Our software and AI technologies are developed at the leading edge:
- Medicine and Healthcare - first-hand experience in patient care, laboratory methods, healthcare trends, regulations and policies.
- Diagnostic Tool Development - identifying specific market needs and commercializing widespread solutions.
Experienced Digital Cytology Management Team
We have united noted leaders from computer science, cytopathology, and diagnostic systems development to bring a meaningful change to cytology. Our team includes executive leaders, physicians, award-winning cytopathologists and leaders including contributing authors of The Paris System (TPS) for Reporting Urinary Cytology. Together, we are creating the future of cytology by bringing forward abnormal cells including their respective quantitative information to improve reporting and patient care.
AIxMed. Beyond Human (in)sight.
Samuel Chen
Chief Executive Officer, President & Co-Founder
Dr. Tien-Jen Liu
Chief Operating Officer & Co-Founder
Stephen Hess
SVP Business Development
Dr. Barbara Crothers
Chief Scientist
Accomplished Advisory Board
Dr. HJ Chang
- Board of Director, AIxMed
- Chairman & CEO, Taiwan Global BioFund
- Former Deputy Minister, Dept of Health, Taiwan
Mr. Shawn Marcell
- Board of Director, AIxMed
- President/CEO, Bifrost Biosystems
- Entrepreneur In Residence/Visiting Scholar, Wyss Institute, Harvard
Dr. Liron Pantanowitz
- Chair, Department of Pathology, UPMC
- President, Digital Pathology Association (DPA)
- President, American Society of Cytopathology
Dr. Christopher VandenBussche
- Professor of Pathology at The Johns Hopkins University School of Medicine
- Associate Director, Cytopathology Division at Johns Hopkins Hospital